Table 2.
Treatment of non-surviving and surviving patients.
| Survivors (n = 62) |
Non-survivors (n = 10) |
P value | |
|---|---|---|---|
| Respiratory support – n (%) | 0.38 | ||
| Conventional oxygen therapy | 2 (3.2) | 0 | |
| High-flow nasal cannula | 7 (11.3) | 0 | |
| Non-invasive mechanical ventilation | 6 (9.7) | 0 | |
| Invasive mechanical ventilation | 47 (75.8) | 10 (100) | |
| Neuromuscular blockers – n (%) | 41 (66.1) | 7 (70.0) | 0.99 |
| Prone position – n (%) | 19 (30.6) | 5 (50.0) | 0.29 |
| Lopinavir/Ritonavir – n (%) | 58 (93.5) | 9 (90.0) | 0.54 |
| Hydroxychloroquine – n (%) | 62 (100) | 10 (100) | – |
| Interferon Beta 1-B – n (%) | 49 (79.0) | 7 (70.0) | 0.68 |
| Tocilizumab – n (%) | 24 (38.7) | 3 (30.0) | 0.73 |
| Steroid agents – n (%) | 38 (61.3) | 6 (60.0) | 0.99 |
| Intermittent renal replacement therapy – n (%) | 1 (1.6) | 0 | 0.99 |
| Continuous renal replacement therapy – n (%) | 8 (12.9) | 3 (30.0) | 0.17 |
| Vasopressors – n (%) | 43 (69.4) | 10 (100) | 0.054 |